Skip to content Skip to sidebar Skip to footer
Página inicial / Tb Again We Saw That the Probability of Contracting Tb Is Small With P About 00005

Tb Again We Saw That the Probability of Contracting Tb Is Small With P About 00005

Postar um comentário

Infection with Mycobacterium tuberculosis (Mtb), i of the most common infections worldwide, remains an important public health problem in the United States. Although the incidence of tuberculosis (TB) cases has declined over the past ii decades, data from 2013 to 2015 testify that rates have plateaued at 3.0 per 100,000 persons (1). In 2015, 9,563 TB cases were reported in the Usa (1).

Latent TB infection (LTBI) is defined every bit a nontransmittable and asymptomatic form of TB, but it tin can progress to active TB affliction. Successful control of TB warrants prompt identification of infected hosts. The detection of LTBI permits early handling and reduces the chance of developing active affliction. Until recently, the tuberculin skin exam (TST) was the chief mode of screening for latent TB. The TST was prone to simulated-positive results in individuals who had been vaccinated with Bacillus Calmette–Guérin (BCG) (2,3) and those who were exposed to nontuberculous mycobacteria. In addition, the TST required manual administration and assessment of the response 48–72 hours later and is decumbent to errors arising from incorrect administration and/or estimation (four).

QuantiFERON-TB Gilt In-Tube (QFT-GIT) Assay serves equally an improved LTBI serologic screening method through indirect measure of Mtb infection. QFT-GIT is an interferon-gamma (IFN-γ) release analysis which detects the in vitro adaptive immune response to specific TB antigens by their production of IFN-γ. Host blood is collected into three samples: the Null tube, Mitogen tube, and TB Antigen tube. The amount of IFN-γ produced in each tube is measured by enzyme-linked immunosorbent assay. IFN-γ values from the Nil tube are subtracted from the TB Antigen tube to correct for the corporeality of IFN-γ which is not induced past the specific TB antigens but considered as groundwork. TB Antigen minus Nil IFN-γ levels over 0.35 IU/mL bespeak a positive test. In addition, Cypher tube values must not be higher than 8.0 IU/mL, which could otherwise signal a false-positive upshot. Tests with corresponding Mitogen tube responses less than 0.5 IU/mL higher than the value of the Zip tube are labeled "indeterminate," as this tube is used every bit an indication of the patient's immune status and maintenance of proper testing techniques (5). Unlike the TST, the QuantiFERON test is reliable in individuals vaccinated with BCG. A positive QuantiFERON test effect indicates that TB infection is likely; even so, a positive QuantiFERON examination cannot discern between LTBI and active TB disease.

In our practise, because TB disease tin can mimic many neuro-ophthalmic disorders, QuantiFERON has replaced the TST as the screening test for TB. We hypothesized that the QFT-GIT is non beneficial equally a screen for TB affliction in patients at low-individual risk for TB. We retrospectively reviewed 99 cases of QFT-GIT testing in 2 neuro-ophthalmologic clinics in Houston, TX to determine the diagnostic yield of such testing.

METHODS

Patient records from 2 academic ophthalmology centers, located in a individual (Hospital A) and a public (Hospital B) healthcare setting, were reviewed from January 2012 to Feb 2016. QFT-GIT results were divided into 3 groups: 1) negative, 2) indeterminate, and 3) positive. All patients with positive examination results had at least 6 months of follow-upwards. Patients were excluded if they had a previous diagnosis of active TB disease or LTBI. Patients were defined as having LTBI if they had a positive QFT-GIT but negative bacteriologic cultures (if performed), and no clinical symptoms or signs, bacteriologic confirmation, or chest radiographic testify of active TB affliction (6). Patients were defined equally having active TB if they had clinical, bacteriologic, and/or radiographic evidence of active TB (half dozen). Patients were defined as not having active TB which affects ocular function if they had a negative reaction to a QFT-GIT test, regardless of previous exposure to TB (6).

Quality control mechanisms at the two testing laboratories were investigated. Protocols for the retesting of positive, indeterminate, and deadline specimens were intact for the verification of test results (seven). In addition, strict criteria for the handling and processing of samples were in place at both testing locations.

RESULTS

A total of 99 patients with QFT-GIT testing were included. Of these 99 patients, 72 (73%) had negative QFT-GIT testing, xviii had positive, and ix had indeterminate results. Of the 18 patients with positive tests, 12 had documentation of chest radiographs or computed tomography which showed no evidence for either active TB or LTBI, indicating potential simulated-positive QFT-GIT results. Four patients had chest imaging indicative of potential LTBI, while two could not be contacted regarding results of chest radiography. None of these 18 patients had symptoms of agile TB, and none developed active TB inside the follow-upward menstruation. These results are summarized in Table one. Demographic data, examination findings, laboratory and imaging results, and clinical class are shown in Supplemental Digital Content, (see Tabular array E1, https://links.lww.com/WNO/A216). QFT-GIT testing results are found in Tabular array two.

T1
Tabular array 1.:

Results of QuantiFERON-TB gilded in-tube assay and chest imaging

T2
TABLE ii.:

Summary of QuantiFERON-TB Gilded In-Tube (QFT-GIT) results in patients with positive QFT-GIT testing and negative chest imaging for pulmonary tuberculosis

Infirmary A had a rate of LTBI detection of 8.4% between 2012 and 2015. This rate was significantly higher at Hospital B, where 22% of patients were shown to have LTBI past QuantiFERON testing performed between 2012 and 2016 (8). Despite the disparity, a similar prevalence of positive QFT-GIT testing with negative neuro-ophthalmic findings was found at both hospitals: 16% for Infirmary A (non including ii patients who did not accept breast radiographs) and 15.half-dozen% for Hospital B (Table 1).

Give-and-take

Despite its widespread use for the diagnosis of LTBI, QFT-GIT testing has been shown to be neither sensitive nor specific for detection of active TB illness (9,ten). In our study, nosotros had a rate of 67% (12/18 patients) faux-positive QFT-GIT testing. LTBI was identified through chest radiography in 4 of our eighteen patients who had positive QFT-GIT tests. Six of the 12 patients with positive QFT-GIT testing and negative chest imaging for LTBI showed no sign of active TB during the follow-up menstruation. The high number of patients with normal chest imaging in our report is consequent with findings of Fong et al (11) who found that only four.one% of 484 health care workers with positive QFT-GIT test results had abnormalities on chest radiographs, and none developed active pulmonary TB. It is notable that almost of our cases of false-positive results were found in patients presenting with optic neuropathies and/or optic atrophy (see Supplemental Digital Content, Table E1, https://links.lww.com/WNO/A216). Further study in a larger patient cohort might determine which clinical presentations yield a higher risk for development of TB-related ocular affliction.

We believe that routine testing with QFT-GIT in a depression-risk accomplice is unnecessary and we practice not recommend routine testing for such low-risk individuals. Factors which would indicate a patient is at depression risk for TB affecting ocular function include low prevalence of TB in a particular geographic region, lack of potential patient exposure (e.g., close contacts with individuals with TB, residence in an owned land, recent incarceration, or homelessness), examination findings indicative of an culling disease process, and lack of medical history increasing the patient'due south risk for active TB, such equally immunosuppressive states including HIV, astringent kidney disease, AIDS fewer than v years, and immunosuppressive and immunomodulatory therapy (12–16).

Low-risk status lowers the pretest probability of TB detected past QFT-GIT leading to a lower positive predictive value of QFT-GIT and a higher charge per unit of false-positive results. For progression to active TB, the positive predictive value for interferon-gamma release assays (IGRAs) such equally QFT-GIT, which measure the in vitro immune response to antigens from IFN-γ–releasing cells, increased significantly with high-risk individuals. This supports our recommendation of targeted testing based on pretest probability (17,18). Notably, a low cut point when retesting a low-risk population could increment the false-positive charge per unit of QFT-GIT testing (ix,xix–21). We advocate a directed arroyo to determine the need for QFT-GIT based on pretest probability of TB disease in patients with neuro-ophthalmic disorders.

Several well-described limitations exist regarding use of the QFT-GIT, including a pregnant amount of variability (11,22). A systematic review of 26 studies, including those with both identical and nonidentical protocols, found variability in IFN-γ response (±0.47 IU/mL) to QuantiFERON fifty-fifty under identical weather condition. In nonidentical protocols, the range of variability was fifty-fifty larger (±ane.4 IU/mL) (23). Variations in laboratory techniques, such as varied incubation time and inoculum volume, can atomic number 82 to indeterminate or false-positive results, rather than increased examination sensitivity (24,25). Although electric current recommendations to ostend a positive QFT-GIT examination in a depression-risk setting include repeat testing, the rate at which positive tests will revert to a negative value on repeat testing has been shown to range from 7% reversion at immediate retesting with the aforementioned plasma sample to 87.5% reversion with repeat testing at 1 yr (7,11,xx,21,26–29). As the QFT-GIT test measures released quantities of IFN-γ from T cells in the peripheral blood, daily variations in this level could be explained past the number of T cells at whatever once, especially if these fluctuations are shut to the cutoff of 0.35 IU/mL (11,30). Based on inherent ranges of for test variability, Metcalfe et al (21) found that positive QFT-GIT exam results less than 0.59 IU/mL could be expected to revert back to negative on repeated testing. Iii of our 12 positive tests were less than 0.59 IU/mL. In addition, Thanassi et al (31) establish that if the QFT-GIT result was positive between 0.35 and 1.11 IU/mL, then a 75% risk of reversion occurred with sequential testing, and an fourscore% risk of reversion occurred if the QFT-GIT result was between 0.35 and 0.72 IU/mL. Viii of our examination results savage into the former category, whereas v patients fell into the latter data range, indicating high likelihood for reversion.

There is an additional IGRA for detection of LTBI: the T-SPOT.TB examination. In this analysis, peripheral claret mononuclear cells are incubated with 2 of the 3 active synthetic peptides found in Mtb that are used in QFT-GIT, and so T cells producing IFN-γ are measured with an immunospot assay (18). As multiple studies have indicated, T-SPOT.TB and QFT-GIT tests have shown discordant results. It is possible that the T-SPOT.TB assay might potentially yield more authentic results for detection of TB in neuro-ophthalmic patients (18,28). Nevertheless, in comparing IGRAs (including both T-SPOT.TB and QFT-GIT) and TST, it was institute that no available tests for LTBI have a loftier prognostic value, and that only a weak-to-moderate clan exists between positive IGRA assays and the evolution of active TB (32).

We recognize the limitations of our study, including the retrospective analysis, the relatively small-scale sample size, and the brusk elapsing of follow-up. Although we only accept followed our patients for v months to iv years, the lifetime risk of LTBI converting to an active TB infection is v%–x%. The loss of follow-upwards of 2 of the 18 positive QFT-GIT testing patients, with failure to undergo chest imaging, is another limitation. Our written report did not clarify the nine of the 99 patients with indeterminate results; retesting could have changed the proportion of patients with positive or negative results. Although no patient with indeterminate results developed TB illness during the follow-up flow, the implications for indeterminate testing remain unclear. We did not make up one's mind the charge per unit of false-negative QFT-GIT testing. To our knowledge, none of our 99 patients developed active TB disease over the follow-up period, and none of the patients with negative testing progressed to LTBI using culling testing methods.

In summary, the 18 positive QFT-GIT assays studied in a neuro-ophthalmologic setting did not accept prognostic significance in the detection or development of ocular TB in patients from 5 months to 4 years of follow-up. The results of this retrospective accomplice report, aslope current literature demonstrating the intrinsic variability of the QFT-GIT and high rates of fake positivity in low-risk populations, lead united states to recommend against universal screening for ocular TB using QFT-GITs in favor of directed testing toward individuals at high risk for disease with the most sensitive and specific test available.

STATEMENT OF AUTHORSHIP

Category one: a. Conception and blueprint: L. M. Little, Thousand. Rigi, A. Suleiman, S. V. Smith, E. A. Graviss, R. Foroozan, and A. G. Lee; b. Conquering of data: Fifty. 1000. Petty, R. Foroozan, and A. G. Lee; c. Analysis and interpretation of data: 50. Thou. Little, M. Rigi, A. Suleiman, S. V. Smith, E. A. Graviss, R. Foroozan, and A. Thou. Lee. Category 2: a. Drafting the manuscript: L. G. Picayune, M. Rigi, A. Suleiman, South. 5. Smith, Eastward. A. Graviss, R. Foroozan, and A. G. Lee; b. Revising it for intellectual content: L. M. Trivial, M. Rigi, A. Suleiman, S. V. Smith, Eastward. A. Graviss, R. Foroozan, and A. 1000. Lee. Category 3: a. Concluding approval of the completed manuscript: L. M. Little, Grand. Rigi, A. Suleiman, South. V. Smith, E. A. Graviss, R. Foroozan, and A. Thousand. Lee.

ACKNOWLEDGMENTS

The authors thank Dr. Charles Stager, Dr. Robert Atmar, and Anthony Cordova for supplementation of data for QuantiFERON-Gold In-Tube Analysis results within the Harris Health Organisation.

REFERENCES

1. Salinas JL, Mindra One thousand, Haddad MB, Pratt R, Price SFLA. Leveling of tuberculosis incidence—Us, 2013–2015. Centers Dis Control Prev Morb Mortal Wkly Rep. 2016;65:273–278.

  • Cited Here

2. Vinton P, Mihrshahi Southward, Johnson P, Jenkin GA, Jolley D, Biggs BA. Comparison of QuantiFERON-TB Aureate In-Tube Test and tuberculin peel test for identification of latent Mycobacterium tuberculosis infection in healthcare staff and association between positive test results and known adventure factors for infection. Infect Command Hosp Epidemiol. 2009;30:215–221.

  • Cited Here

3. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ. Discrepancy betwixt the tuberculin skin exam and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-brunt state. JAMA. 2005;293:2756–2761.

  • Cited Hither

4. Diel R, Loddenkemper R, Niehaus A. Bear witness-based comparison of commercial interferon-γ release assays for detecting active TB: a metaanalysis. Chest. 2010;137:952–968.

  • Cited Here

5. QuantiFERON-TB Gold What is QuantiFERON-TB Gold? QIAGEN. Available at: http://www.quantiferon.com/irm/content/quantiferon-tb-gold1.aspx?RID=300. Accessed March 22, 2016.

  • Cited Here

6. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Command and Prevention was adopted by the ATS Lath of Directors, July 1999. This statement was endorsed by the Council of the Infectious disease Society of America, September 1999. Am J Respir Crit Care Med. 2000;161:1376–1395.

  • Cited Here

7. Mazurek GH, Jereb J, Vernon A, Lobue P, Goldberg South, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States. MMWR Recomm Rep. 2010;59:1–25.

  • Cited Here

eight. Cordova A, Stager C. Data request: rates of LTBI positivity. Harris Health Syst. 2016.

  • Cited Here

9. Daley CL, Reves RR, Beard MA, Boyle J, Clark RB, Beebe JL, Catanzaro A, Chen L, Desmond E, Dorman SE, Hudson TW, Lardizabal AA, Kapoor H, Marder DC, Miranda C, Narita M, Reichman 50, Schwab D, Seaworth BJ, Terpeluk P, Thanassi West, Kawamura LM. A summary of meeting proceedings on addressing variability around the cut point in serial interferon-γ release assay testing. Infect Control Hosp Epidemiol. 2013;34:625–630.

  • Cited Here

ten. Mancuso JD, Mazurek GH, Tribble D, Olsen C, Aronson NE, Geiter 50, Goodwin D, Continue LW. Discordance amidst commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2012;185:427–434.

  • Cited Here

11. Fong KS, Tomford JW, Teixeira L, Fraser TG, van Duin D, Yen-Lieberman B, Gordon SM, Miranda C. Challenges of interferon-γ release analysis conversions in serial testing of health-care workers in a TB command plan. Chest. 2012;142:55–62.

  • Cited Here

12. Centers for Illness Control and Prevention. Tuberculosis (TB). Available at: http://www.cdc.gov/tb/default.htm. Accessed March 22, 2016.

  • Cited Here

13. Gupta V, Shoughy SS, Mahajan S, Khairalla Chiliad, Rosenbaum J, Curi A, Tabbara M. Clinics of ocular tuberculosis. Ocul Immunol Inflamm. 2015;23:14–24.

  • Cited Hither

14. Morinelli EN, Dugel PU, Riffenburgh R, Rao NA. Infectious multifocal choroiditis in patients with caused allowed deficiency syndrome. Ophthalmology. 1993;100:1014–1021.

  • Cited Here

15. Sudharshan S, Kaleemunnisha S, Banu AA, Shrikrishna South, George AE, Babu BR, Devaleenal B, Kumarasamy Due north, Biswas J. Ocular lesions in 1,000 consecutive HIV-positive patients in India: a long-term written report. J Ophthalmic Inflamm Infect. 2013;3:2.

  • Cited Here

16. US Preventive Services Job Force, Bibbins-Domingo Grand, Grossman DC, Back-scratch SJ, Bauman L, Davidson KW, Epling JW, García FA, Herzstein J, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Pignone MP. Screening for latent tuberculosis infection in adults: Usa preventive services task force recommendation statement. JAMA. 2016;316:962–969.

  • Cited Hither

17. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin pare testing for progression from latent TB infection to illness state: a meta-analysis. Chest. 2012;142:63–75.

  • Cited Here

18. Person AK, Pettit AC, Sterling TR. Diagnosis and handling of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013;2:199–207.

  • Cited Here

19. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai K. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax. 2012;67:62–seventy.

  • Cited Here

xx. QuantiFEROn-TB Aureate (QFT) ELISA Package Insert. Chadstone, Australia: Cellestis, a QIAGEN Company, 2013.

  • Cited Hither

21. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB golden in-tube assay in clinical practice. Am J Respir Crit Care Med. 2013;187:206–211.

  • Cited Here

22. Ringshausen FC, Nienhaus A, Costa JT, Knoop H, Schlösser Southward, Schultze-Werninghaus 1000, Rohde G. Inside-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers. Clin Vaccin Immunol. 2011;18:1176–1182.

  • Cited Here

23. Tagmouti S, Slater M, Benedetti A, Kik SV, Banaei Due north, Cattamanchi A, Metcalfe J, Dowdy D, van Zyl Smit R, Dendukuri Northward, Pai M, Denkinger C. Reproducibility of interferon gamma (IFN-γ) release assays. A systematic review. Ann Am Thorac Soc. 2014;11:1267–1276.

  • Cited Here

24. Min JW, Lee HY, Lee JS, Lee J, Chung JH, Han SK, Yim JJ. Upshot of prolonged incubation time on results of the QuantiFERON TB gold in-tube analysis for diagnosis of latent tuberculosis infection. Clin Vaccin Immunol. 2013;twenty:1377–1380.

  • Cited Here

25. Gaur RL, Pai M, Banaei Due north. Impact of claret volume, tube shaking, and incubation fourth dimension on reproducibility of QuantiFERON-TB gold in-tube assay. J Clin Microbiol. 2013;51:3521–3526.

  • Cited Here

26. Gamsky TE, Lum T, Hung-Fan Yard, Green JA. Cumulative false positive QuantiFERON-TB Interferon-Gamma release assay results. Ann Am Thorac Soc. 2016;thirteen:660–665.

  • Cited Hither

27. Slater ML, Welland G, Pai Yard, Parsonnet J, Banaei N. Challenges with QuantiFERON-TB gold assay for large-scale, routine screening of U.S. healthcare workers. Am J Respir Crit Care Med. 2013;188:1005–1010.

  • Cited Here

28. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter LD, Parker Grand, Garrett Do, Daley CL, Tuberculosis Epidemiologic Studies Consortium. Interferon-γ release assays and tuberculin pare testing for diagnosis of latent tuberculosis infection in healthcare workers in the United states of america. Am J Respir Crit Care Med. 2014;189:77–87.

  • Cited Here

29. Zwerling A, Benedetti A, Cojocariu M, McIntosh F, Pietrangelo F, Behr MA, Schwartzman M, Menzies D, Pai M. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One. 2013;8:i–10.

  • Cited Here

30. Detjen AK, Loebenberg L, Grewal HMS, Stanley M, Gutschmidt A, Kruger C, Plessis ND, Kidd 1000, Beyers North, Walzl G, Hesseling Air-conditioning. Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccin Immunol. 2009;16:1170–1175.

  • Cited Here

31. Thanassi W, Noda A, Hernandez B, Newell J, Terpeluk P, Marder D, Yesavage JA. Delineating a retesting zone using receiver operating characteristic analysis on series quantiFERON tuberculosis test results in US healthcare workers. Pulm Med. 2012;2012:291294.

  • Cited Hither

32. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinsin R, Pai M. Predictive value of interferon-γ release assays for incident agile tuberculosis: a systematic review and meta-assay. Lancet Infect Dis. 2012;12:45–55.

  • Cited Here

Supplemental Digital Content

Copyright © 2017 by North American Neuro-Ophthalmology Lodge

wellswhed1967.blogspot.com

Source: https://journals.lww.com/jneuro-ophthalmology/Fulltext/2017/09000/The_QuantiFERON_TB_Gold_In_Tube_Assay_in.5.aspx

Talvez você goste destas postagens

Postar um comentário for "Tb Again We Saw That the Probability of Contracting Tb Is Small With P About 00005"